Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatitis C: early-phase trial registry
13 of 108 indexed Hepatitis C trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #119 of 28,707 conditions by registered trial count.
108 US clinical trials · 13 currently recruiting · #119 of 28,707 conditions by registered trial count
Hepatitis C: 108 US clinical trials tracked, 13 recruiting.
Hepatitis C is the subject of 108 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 7 of these trials.
Enrollment posture brief
Registry condition hepatitis-c
OPEN 13 | RECR 12% | LATE 21 | EARLY 37 | RANK #119 | SPON 7
Volume-matched condition peers
Nearest open-share peer: HIV Infection (12% recruiting · 74 trials)
Hepatitis C lists 13 open slots (12% of 108 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatitis C on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatitis C is recruiting below its size-band peers.
13 of 108 indexed trials (12%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatitis C trials is spread across many organizations.
Gilead Sciences accounts for 7 of 108 trials (6.5%). 67 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatitis C enrolment sits around 115 participants.
Median target enrolment is 115 among the 107 trials that report a genuine target (sentinel values excluded). 49 of those (45.8%) plan for fewer than 100 participants.
-
Hepatitis C research is mostly interventional.
86 interventional and 22 observational studies make up this index (79.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
108 total, page 2 of 3
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers
Icahn School of Medicine at Mount Sinai
NCT00211848
Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening
Rhode Island Hospital
NCT04137094
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Bristol-Myers Squibb
NCT02032901
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Bristol-Myers Squibb
NCT01795911
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Bristol-Myers Squibb
NCT01309932
Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Nizar Zein
NCT00512278
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
University of California, San Francisco
NCT03619837
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Boehringer Ingelheim
NCT01330316
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
Vertex Pharmaceuticals Incorporated
NCT00535847
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
Medtronic Corporate Technologies and New Ventures
NCT00919633
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
Human Genome Sciences
NCT00097435
Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2
TriHealth
NCT03320889
TD-6450 SAD and MAD in Healthy Subjects
Theravance Biopharma
NCT02022306
Anticipated and Perceived Benefits Following Hepatitis C Treatment
University of North Carolina, Chapel Hill
NCT03000023
HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention
Montefiore Medical Center
NCT03242655
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
University of Maryland, Baltimore
NCT03823911
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
GlaxoSmithKline
NCT00110799
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
Fernanda P Silveira, MD, MS
NCT03819322
Evaluation of HepCure Toolkit to Improve Harvoni Adherence
Icahn School of Medicine at Mount Sinai
NCT02740556
Helping Empower Liver and Kidney Patients
Washington University School of Medicine
NCT03426787
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
Conatus Pharmaceuticals
NCT01051921
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
NCT01559844
GS-7977 With Ribavirin for Hepatitis C (SPARE)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01441180
History of Hepatitis C in Volunteer Blood Donors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001982
Phase I Trial of Silymarin for Chronic Liver Diseases
National Center for Complementary and Integrative Health (NCCIH)
NCT00389376
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
Abbott
NCT00982826
Eliminating Hepatitis C Virus
Icahn School of Medicine at Mount Sinai
NCT03401697
Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults
University of Massachusetts, Worcester
NCT01472354
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
Astellas Pharma
NCT00047814
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Gilead Sciences
NCT01808248
TD-6450 MAD Study in HCV Infected Subjects
Theravance Biopharma
NCT02116543
Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
National Institute on Drug Abuse (NIDA)
NCT00218556
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
GlaxoSmithKline
NCT00833378
HCV Seek, Test and Rapid Treatment for Young PWID
Weill Medical College of Cornell University
NCT03627546
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01888900
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
Peregrine Pharmaceuticals
NCT00128271
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
University of California, San Francisco
NCT00879047
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01165359
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00393276
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
Enanta Pharmaceuticals
NCT01856426
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
University of Colorado, Denver
NCT01427504
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
Timothy Morgan, MD
NCT02098616
Open-Label Hepatic Impairment Study
Gilead Sciences
NCT01497327
Treatment of Hepatitis C in Hemophilic Patients With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00055341
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
University of California, San Francisco
NCT00845676
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
GlaxoSmithKline
NCT01424540
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
Vertex Pharmaceuticals Incorporated
NCT01038167
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
Brooke Army Medical Center
NCT00926614
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Baylor College of Medicine
NCT01988753
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
Bader, Ted, M.D.
NCT00446940
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 23 |
| Phase 3 | 11 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatitis C records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatitis C trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatitis C page
108 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Hepatitis C trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most Hepatitis C trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis C condition card totals 108 registered trials; most-linked intervention Ribavirin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.